key: cord-0719257-dr2u9jso authors: Pertejo, A.; Recio, S. Martinez; Jimenez-Bou, D.; Peña-Lopez, J.; Ruiz-Gutierrez, I.; Martín-Montalvo Pérez, G.; Rueda-Lara, A.; Marin, V. Martinez title: 1582P Thromboembolic disease in COVID-19 cancer patients: Impact on overall survival and prognostic factors date: 2021-09-30 journal: Annals of Oncology DOI: 10.1016/j.annonc.2021.08.1575 sha: c42cfbebac0bc634a142fc3a02a85cf41f6cc001 doc_id: 719257 cord_uid: dr2u9jso Background: An increased risk of thromboembolic events (TE) is associated with COVID-19 infection. However, information available about thrombosis risk in COVID-19 cancer patients (Ca-P) is still scarce. Methods: We retrospectively evaluated 219 Ca-P who were diagnosed of COVID-19 infection in our institution during the first pandemic wave. The study population was monitored for 12 months, and TE were recorded. A descriptive analysis of baseline and follow-up clinical characteristics was performed. Potential prognostic factors for developing TE and overall survival (OS) were analysed using logistic and cox proportional regression models. Results: Overall TE rate was 13%. TE were reported during COVID-19 hospitalization (52%) and during follow-up (48%), the median time from COVID-19 diagnosis to TE was 12 weeks (w). Reported TE included pulmonary embolism (68%), deep vein thrombosis (16%), and other arterial thrombosis (16%). Pooled mortality rate among patients with TE was 52%, and 41% among patients without TE. Univariate analysis revealed haemoglobin <10g/dL, D-dimer >3000 ng/mL, PCR >5 ng/mL, LDH >190 UI/L and ferritin > 296 ng/mL during follow-up as significant prognostic factors for TE. Only ferritin > 296 ng/mL remained significant after multivariate analysis. Neither being on any specific oncological treatment nor prior anticoagulant therapy influenced TE risk. No differences in OS were found between patients who developed TE and those who did not. Though, diagnosis of TE during COVID-19 hospitalization conferred poorer survival (12 vs 52 w, p=0.02). Also, being hospitalized for COVID-19 infection was a prognostic factor for worse survival (27 vs 52 w, p=0.03). On multivariate analysis, only acute respiratory distress syndrome, metastatic disease, poor performance status, and history of TE before COVID-19 diagnosis remained significant predictors for poorer survival, and thromboprophylaxis during COVID-19 hospitalization as a predictor for better survival outcomes. Conclusions: TE in COVID-19 Ca-P can lead to fatal outcomes. Thrombotic risk may persist after acute infection;therefore, routine active surveillance should be considered. Larger studies are needed for developing a risk prediction tool for TE in COVID-19 Ca-P. Legal entity responsible for the study: The authors. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest. outcome was asymptomatic disease. Associations between demographic or clinical characteristics and outcomes were measured with odds ratios (ORs) with 95% CIs using multivariable logistic regression. Results: 132 patients were included(18,5% of global ACHOCC-19 cohort). 18,2% died and 25,8% was asymptomatic. In relation to the patients who died vs did not died, 68 vs 66% were > 50 years, 20 vs 10,2% with obesity, 32 vs 51,4% without comorbidities: 24 vs 12% with Diabetes, 56 vs 29% arterial Hypertension, 17,75 vs 3.88% ECOG >2, 50 vs 12,5% progressive cancer, 20 vs 5,6% bacterial coinfection, 65 vs 25,2% received antibiotic and 68 vs 19% steroids for Covid-19 infection. 11.3% had severe infection and received ventilatory support and 66% died. About the asymptomatic patients 74% were > 50 years, 2,9% had obesity, 56% without comorbidities, 56% with ECOG 0 and 17,6% had metastatic disease. In the logistic regression analysis, age > 50 years (OR 2, 7 95% 0, 81), >2 comorbidities (OR 3, 48 95% 0, (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) 71) , progressive disease (OR 3, 52 95% 0, 57) , steroids (OR 6, 62 95% 1, 6 ) and antibiotic treatment for Covid19 (OR 6, 88 95% 1, 76) behaved as a risk factors for mortality, but only steroids and antibiotic was statistically significant. Conclusions: In our study, breast cancer patients have high mortality by Covid-19 infection. Age, comorbidities, ECOG >2, progressive disease, and use of antibiotic and steroids are factors for worse prognosis. Legal entity responsible for the study: The authors. Funding: Has not received any funding. Background: Since the beginning of the COVID-19 pandemic, over 400,000 Brazilians have died and its impact on other diseases is yet to be revealed. Due to contingency strategies, there was a significant reduction in screening programs and this will probably affect cancer treatment outcomes. There is no updated national data regarding the real impact on delaying diagnosis and cancer treatment in Brazil. Objective: To analyze whether the COVID-19 pandemic impacted delaying cancer treatment, yielding more advanced cases as analyzing patients' clinical features before oncological treatment. Methods: This is a retrospective cross-sectional study with patients assisted in a public cancer center in southeastern Brazil between 2019 and 2020 with a comparison of patients' clinical features in both years. We analyzed all 207 patients with head and neck treated in 2019 and 2020 (85 and 122 patients, respectively) and stratified them by clinical stage (CS), tumor size, lymph node status (LNS), the occurrence of metastatic disease (MD), body mass index (BMI), need of enteral nutrition, age, performance status (PS) and the indication of exclusive palliative care. We performed comparisons between these groups using Student t-test and chi-square test with a significance level of 5%. The real impact of the COVID-19 pandemic in cancer treatment is yet to be discovered but so far, our results from 2020 patients indicated a tendency of advanced primary tumor size at the time of cancer diagnosis. Legal entity responsible for the study: The authors. Funding: Has not received any funding. Methods: We retrospectively evaluated 219 Ca-P who were diagnosed of COVID-19 infection in our institution during the first pandemic wave. The study population was monitored for 12 months, and TE were recorded. A descriptive analysis of baseline and follow-up clinical characteristics was performed. Potential prognostic factors for developing TE and overall survival (OS) were analysed using logistic and cox proportional regression models. Results: Overall TE rate was 13%. TE were reported during COVID-19 hospitalization (52%) and during follow-up (48%), the median time from COVID-19 diagnosis to TE was 12 weeks (w Conclusions: TE in COVID-19 Ca-P can lead to fatal outcomes. Thrombotic risk may persist after acute infection; therefore, routine active surveillance should be considered. Larger studies are needed for developing a risk prediction tool for TE in COVID-19 Ca-P. Legal entity responsible for the study: The authors. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest. https://doi.org/10.1016/j.annonc.2021.08.1575 1583P COVID-19 related risk in patients enrolled in early-phase clinical trials P. D'Amico 1 , P. Trillo 1 , S. Morganti 1 , C. Corti 1 , G. Vivanet 1 , E. Crimini 1 , L. Ascione 1 , P. Tarantino 1 , G. Antonarelli 1 , M. Locatelli 1 , A. Esposito 1 , C. Belli 1 , G. Curigliano 2 Early phase clinical trials often represent a therapeutical opportunity for cancer patients (pts). However, high logistic commitment is demanded for participation. Here we explore the COVID-19 related risk during the pandemic for pts enrolled in clinical trials compared to pts receiving standard treatments. Methods: We retrospectively assessed the incidence of COVID-19 in pts treated in our Department from Pts in A were younger, with a median age of 55 years (range 39-77) compared to 62 years (range 31-83) in B. Performance status (PS, ECOG) was similarly distributed: 0 (A 78%, B 83%), 1-2 (A 22%, B 17%). The median of previous treatment was 1 in A (range 0-9) and 2 (range 0-14) in B. The majority of the pts had at least one comorbidity in both groups (A: 72% and B: 83%). None of the pts had pulmonary comorbidity in A and 6% in B. Obesity was similarly distributed (A 11%, B 14%). The mean of monthly scheduled accesses was 1,5 in both groups. However, teleconsultation and delivery of oral cancer treatments at home were given, at least on one occasion Conclusions: Pts enrolled in early phase clinical trials had a significantly lower chance to perform teleconsultations compared to pts receiving standard therapy. Even if a trend was observed, they did not have a higher risk of contracting COVID